Presentation of An Vermeersch
-
Upload
vlerickalumni -
Category
Business
-
view
76 -
download
1
Transcript of Presentation of An Vermeersch
GSK’sVaccines Business
An Vermeersch
105 February 2015
GSK: A science-led global healthcare company
6
£26.5bn2013 group turnover
Pharmaceuticals VaccinesConsumer Healthcare
Source: GSK 2013 Annual Report – Published Feb 2014 - http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report/ VGBU/VAC/0003/14
A global presence
3VGBU/VAC/0003/14
Vaccines in Belgium: Rixensart, Wavre, Gembloux
427/02/2015
deaths prevented every year by vaccination
The value of vaccination
5
children saved from disability every year
the benefit of vaccines to low-and middle-income countries
over the next 10 years
estimated annual healthcare savings over the lifetime of the people born that year in the US
Sources: 1.Ereth, J. Vaccine 2003; 21:4111 2.GAVI Alliance Partners’ Forum, December 2012 reported by JHB School of Public Health. 3.Immunization and Infectious Diseases. Healthypeople.gov. June 2013
3 million1 750,000 1 $150bn 2 $43bn3
Only clean drinking water rivals vaccination in its ability to save lives
To the global economyTo global health
VGBU/VAC/0003/14
We are proud of the role we have played
6
Improving affordability
through tiered pricing
30+licensed vaccines
Rigorousclinical trials
worldwide
Over 100partnerships in
R&D alone
40%of the world’s children receive our vaccines
16candidate vaccines in
development
One standardall over the world
Successin partnerships &
collaborative ventures
Innovation
GSK 2013 Annual Report , published February 2014. http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report VGBU/VAC/0003/14
Big global challenges remain
7
Human
children under 5 die every day from largely preventable diseases2
22 millionchildren without access to vaccines1
19,000
Scientific
people, mostly children, died from
malaria in 20123
34 million
630,000
people were living with
HIV in 20114
approximate proportion of the global disease burden borne by Africa5
25%
Economic
$550 millionaverage cost of a new vaccine
manufacturing facility6
Sources: 1. WHO . References April 2013. http://www.who.int/campaigns/immunization-week/2013/event/en/., 2. UNICEF. Millennium Development Goals 2015.
http://www.unicef.org/mdg/index_childmortality.htm, 3. WHO December 2013. Available from: http://www.who.int/mediacentre/factsheets/fs094/en/, 4. WHO. Available from: http://www.who.int/gho/hiv/en/ [last
accessed Dec 2013], 5. WHO, 2013 World Health Statistics report. http://www.who.int/gho/publications/world_health_statistics/EN_WHS2013_TOC.pdf, 6. GSK data on file. 2013.
VGBU/VAC/0003/14
A series of environmental challenges and opportunities
are transforming the market
• Increasing emerging market demand
• Increasing private market demand due to patient information and empowerment
Demand dynamics
• Increased payer sophistication (e.g. GAVI, PAHO)
• Public market price pressure (e.g. EU)
• Differential-priced portfolios from Big-5
• Low-cost competitors compete on price
• Potential price advantage through services and solutions
Price levels
• New entrants compete for share: from developed markets & emerging marketsCompetitive industry
• Near-term emphasis on LCM (e.g., male HPV), rather than new blockbusters
• Mid-term high expectation from new categories (e.g., nosocomial, immunotherapeutics)
Technology
Our promise to the
person we help protect
with our vaccines
9VGBU/VAC/0003/14
Making our vaccines available to as many people as possible
vaccines are delivered every day to people in 170 countries1
vaccines go to developing world2
4 out of 52 million
1. http://www.gsk.com/en-gb/about-us/what-we-do/vaccines/ Last accessed 08/09/14.
2. GSK 2013 Annual Report, P6, published February 2014. 10VGBU/VAC/0003/14
invested in core vaccine R&D in 20131
Innovating where it really matters
£496 million
1.. GSK 2013 Annual Report. http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report
2. http://www.gsk.com/en-gb/research/what-we-are-working-on/product-pipeline/ - last access 08/09/14 11
1 out of 3
of our 16 candidate vaccines target diseases
particularly prevalent in the developing world2
VGBU/VAC/0003/14
Staking our reputation on our quality: One global standard
State-of-the-art
27
clinical development and manufacturing process
World class
facilities with highly committed and qualified people
VGBU/VAC/0003/14
1.GSK 2013 Annual Report. http://www.gsk.com/en-gb/investors/corporate-reporting/annual-report13
Collaborating widely
partnerships in R&D alone1
100+
30 years
of collaborative research to develop our candidate malaria vaccine1
VGBU/VAC/0003/14
That’s our promiseto the person we help protect with our vaccines
helping them to do more, feel better, live longer
1414VGBU/VAC/0003/14